Animax capsules №20
-
All payments are encrypted via SSL
-
Full Refund if you haven't received your order
Composition
Powder for solution for oral administration (cranberry, lemon, lemon with honey, raspberry, blackcurrant) | 1 pack |
active ingredients: | |
paracetamol | 360 mg |
vitamin C | 300 mg |
calcium gluconate monohydrate | 100 mg |
rimantadine hydrochloride | 50 mg |
Rutozida trihydrate (in terms of Rutozid) | 20 mg |
loratadine | 3 mg |
Excipients: aspartame - 30 mg; hypromellose - 10 mg; colloidal silicon dioxide - 20 mg; lactose monohydrate - 4086 mg; food flavoring (cranberry, lemon, lemon with honey, raspberry, blackcurrant) - 21 mg | |
Capsule kit | 1 set |
Capsule P blue | |
active substance: | |
paracetamol | 360 mg |
Excipients: pregelatinized starch - 9 mg; colloidal silicon dioxide - 3 mg; lactose monohydrate - 1.2 mg; Magnesium stearate - 3.8 mg; Polysorbate 80 - 3 mg | |
hard gelatin capsule: gelatin 94.795 mg; Blue patented dye (E131) or brilliant blue dye (E133) - 0.265 mg; titanium dioxide (E171) - 1.94 mg | |
Red Capsule P | |
active ingredients: | |
vitamin C | 300 mg |
calcium gluconate monohydrate | 100 mg |
rimantadine hydrochloride | 50 mg |
Rutozida trihydrate (in terms of Rutozid) | 20 mg |
loratadine | 3 mg |
Excipients: potato starch - 2.2 mg; magnesium stearate - 4.8 mg | |
hard gelatin capsule: gelatin - 94.064 mg; iron dye yellow oxide (E172) - 0.97 mg; iron dye red oxide (E172) - 0.485 mg; Crimson dye (Ponso 4R) (E124) - 0.511 mg; titanium dioxide (E171) - 0.97 mg | |
Description of the dosage form
Powder for solution for oral administration (cranberry, lemon, lemon with honey, raspberry, blackcurrant)
Bag contents - a mixture of powder and granules from almost white to yellow with a greenish tint color with a characteristic smell (cranberry or lemon, or lemon with honey, raspberry, black currant). The presence of single pink granules.
The solution after dissolving the powder - colorless or with a yellowish tinge, slightly turbid, with a characteristic odor (cranberries or lemon, or lemon with honey, raspberries, black currants). The presence of undissolved yellow particles is allowed.
Capsules
Capsules P - solid gelatin number 0, blue. The contents of the capsules are a mixture of powder and granules of white or white with a creamy or pinkish tinge; lumps are allowed.
Capsules P - solid gelatin number 0, red. The contents of the capsules are a mixture of powder and granules from yellow to yellow with a greenish tint and white color, lumps are allowed.
pharmachologic effect
pharmachologic effect - antiviral, antipyretic, angioprotective, antihistamine, analgesic.
Pharmacodynamics
The combined drug has antiviral, interferonogenic, antipyretic, analgesic, antihistamine and angioprotective effects.
Paracetamol has analgesic and antipyretic effects.
Vitamin C participates in the regulation of redox processes, contributes to the normal permeability of capillaries, blood clotting, tissue regeneration, plays a positive role in the development of immune reactions of the body, compensates for vitamin C deficiency
Calcium gluconate, as a source of Calcium ions, prevents the development of increased permeability and fragility of blood vessels, causing hemorrhagic processes in influenza and acute respiratory viral infections, has antiallergic effect (mechanism is unclear).
Rimantadine has antiviral activity against influenza A virus. Blocking M2Channels of influenza A virus, violates its ability to penetrate cells and release ribonucleoprotein, thereby inhibiting the most important stage of viral replication. Induces the production of Interferon alpha and gamma. With influenza B virus, Rimantadine has an antitoxic effect.
Rutoside is an angioprotector. Reduces capillary permeability, swelling and inflammation, strengthens the vascular wall. It inhibits aggregation and increases the degree of red blood cell deformation.
Loratadine - blocker N1- histamine receptors - prevents the development of tissue edema associated with the release of histamine.
Pharmacokinetics
Paracetamol. Absorption is high. Communication with plasma proteins - 15%. Penetrates the BBB. Metabolized in the liver in three main ways: conjugation with glucuronides, conjugation with sulfates, oxidation by microsomal liver enzymes.In the latter case, toxic intermediate metabolites are formed, which are subsequently conjugated with glutathione, and then with cysteine and mercapturic acid. The main cytochrome P450 isoenzymes for this metabolic pathway are CYP2E1 (predominantly), CYP1A2, and CYP3A4 isoenzymes (secondary role). When glutathione is deficient, these metabolites can cause damage and necrosis of hepatocytes. Additional metabolic pathways are hydroxylation to 3-hydroxy Paracetamol and methoxylation to 3-methoxy paracetamol, which are subsequently conjugated with glucuronides or sulfates. In adults, glucuronidation prevails. Conjugated paracetamol metabolites (glucuronides, sulfates and conjugates with glutathione) have low pharmacological (including toxic) activity. Excreted by the kidneys as metabolites, mainly conjugates, only 3% unchanged. In elderly patients, the clearance of the drug decreases and T increases.1/2.
According to the results of clinical studies, the following pharmacokinetic parameters of paracetamol were established: Cmax in blood plasma is achieved with the use of powder in (0.7 ± 0.39) h and amounts to (4.79 ± 1.81) µg / ml, T1/2 equal to (2.73 ± 0.76) h; Cmax in blood plasma is achieved with the use of capsules in (1.2 ± 0.72) h and is (5.01 ± 1.7) µg / ml, T1/2 equal to (3.04 ± 1.01) h.
Vitamin C absorbed in the digestive tract (mainly in the jejunum). Communication with plasma proteins - 25%. Diseases of the digestive tract (peptic ulcer of the stomach and duodenum,constipation or diarrhea, worm infestation, giardiasis), the use of fresh fruit and vegetable juices, alkaline drink reduces the absorption of Ascorbic acid in the intestine. The plasma ascorbic acid concentration is normally around 10-20 μg / ml. Tmax in blood plasma after ingestion - 4 hours. Easily penetrates into leukocytes, platelets, and then into all tissues; the greatest concentration is reached in the glandular organs, leukocytes, liver and lens of the eye; penetrates through the placenta. The concentration of ascorbic acid in leukocytes and platelets is higher than in erythrocytes and plasma. In deficient states, the concentration in leukocytes decreases later and more slowly and is considered as a better criterion for assessing the deficit than the concentration in plasma. Metabolized predominantly in the liver to deoxyascorbic and then to oxaloacetic acid and ascorbate 2-sulfate. Excreted by the kidneys, through the intestines, with then unchanged and in the form of metabolites. Smoking and the use of ethanol accelerate the destruction of ascorbic acid (turning into inactive metabolites), sharply reducing reserves in the body. It is derived during hemodialysis.
Calcium gluconate. Approximately 1 / 5-1 / 3 of orally administered Calcium gluconate is absorbed in the small intestine; This process depends on the presence of ergocalciferol, pH, diet, and the presence of factors capable of binding calcium ions. Absorption of calcium ions increases with its deficiency and the use of a diet with a reduced content of calcium ions.About 20% is excreted by the kidneys, the rest (80%) - by the intestines.
Rimantadine. After ingestion is almost completely absorbed in the intestine. Absorption is slow. Communication with plasma proteins is about 40%. Vd - 17-25 l / kg. Concentration in nasal secretion is 50% higher than plasma. Metabolized in the liver. More than 90% is excreted by the kidneys within 72 hours, mainly in the form of metabolites, 15% - unchanged. With CRF T1/2 increases by 2 times. In patients with renal insufficiency and in elderly people, it can accumulate in toxic concentrations if the dose is not adjusted in proportion to the decrease in Cl creatinine. Hemodialysis has a minor effect on the clearance of rimantadine.
According to the results of clinical studies, the following pharmacokinetic parameters of rimantadine were established: Cmax in blood plasma is achieved with the use of powder in (5.28 ± 2.54) h and is (69 ± 19.7) ng / ml, T1/2 - (33.26 ± 12.76) h; Cmax in blood plasma is achieved with the use of capsules after (4.53 ± 2.52) h and is (68.2 ± 26.6) ng / ml, T1/2 - (30.51 ± 9.83) h.
Rutoside. Tmax in blood plasma after ingestion - 1-9 hours. It is derived mainly from the bile and to a lesser extent by the kidneys. T1/2 - 10-25 h.
Lortadin. Quickly and completely absorbed in the digestive tract. Cmax in the elderly increases by 50%. Communication with plasma proteins - 97%. Metabolized in the liver to form an active metabolite (descarboethoxyloratadine) with the participation of cytochrome CYP3A4 isoenzymes and to a lesser extent CYP2D6. Does not penetrate the BBB. Excreted by the kidneys and with bile. In patients with chronic renal failure and during hemodialysis, the pharmacokinetics are virtually unchanged.
According to the results of clinical studies, the following pharmacokinetic parameters of loratadine were established: Cmax in blood plasma, when receiving the powder, it is reached in (3.28 ± 1.25) hours and amounts to (1.85 ± 0.95) ng / ml, T1/2 equal to (11.29 ± 5.52) h; Cmax in the blood plasma when taking capsules is reached in (2.92 ± 1.31) hours and is (2.36 ± 1.53) ng / ml, T1/2 equal to (12.36 ± 6.84) hours
Indications of Anvimax ®
treatment of type A flu;
symptomatic treatment of colds, influenza and ARVI, accompanied by fever, chills, nasal congestion, sore throat, pain in joints and muscles, headache.
Contraindications
hypersensitivity to one or more components that make up the drug;
erosive and ulcerative lesions of the gastrointestinal tract in the acute phase;
gastrointestinal bleeding;
hemophilia;
hemorrhagic diathesis;
hypoprothrombinemia;
portal hypertension;
vitamin deficiency;
renal failure;
thyroid disease;
acute diseases of the kidneys, liver (acute glomerulonephritis, acute pyelonephritis, acute hepatitis or exacerbation of chronic diseases of these organs);
chronic alcoholism;
hypercalcemia, severe hypercalciuria;
nephrourolithiasis;
sarcoidosis;
simultaneous reception of cardiac glycosides (risk of arrhythmias);
lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
phenylketonuria (for powder to prepare a solution for ingestion);
pregnancy;
breastfeeding period;
children's age up to 18 years.
Carefully: epilepsy; cerebral atherosclerosis; diabetes; glucose-6-phosphate dehydrogenase deficiency; hemochromatosis; sideroblastic anemia; thalassemia; hyperoxaluria; kidney disease; dehydration; electrolyte disturbances (risk of developing hypercalcemia); diarrhea; malabsorption syndrome; calcium nephrolourithiasis (in history); hypercalciuria; elderly patients with arterial hypertension (increased risk of hemorrhagic stroke due to rimantadine, which is part of the drug).
Use during pregnancy and lactation
Use during pregnancy and during breastfeeding is contraindicated.
Side effects
For both dosage forms
In accordance with the constituent components.
From the sideCNS: irritability, drowsiness, tremor, hyperkinesia, dizziness, headache, flushing of the face.
From the digestive system: lesion of the gastric mucosa and the twelve